Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 12/20 | 0.49 |
| ▸ | ACHE | P22303 | 9/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12732043 | 0.99 | BCHE (0.49) | BCHEACHECA12CA9NOS1 | |
| SCHEMBL1657932 | 0.99 | BCHE (0.49) | BCHEACHECA12CA9NOS1 | |
| SCHEMBL1657935 | 0.99 | BCHE (0.49) | BCHEACHECA12CA9NOS1 | |
| SCHEMBL1658123 | 0.92 | CA12 (0.53) | BCHEACHECA12CA9NOS1 | |
| SCHEMBL1658122 | 0.92 | CA12 (0.53) | BCHEACHECA12CA9NOS1 | |
| SCHEMBL1657725 | 0.91 | CA12 (0.54) | BCHEACHECA12CA9NOS1 | |
| SCHEMBL1656982 | 0.91 | CA12 (0.54) | BCHEACHECA12CA9NOS1 | |
| SCHEMBL1657190 | 0.89 | BCHE (0.50) | BCHEACHECA12CA9NOS1 | |
| SCHEMBL1662262 | 0.89 | NAAA (0.43) | BCHEACHE | |
| SCHEMBL1662009 | 0.87 | NAAA (0.44) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946451-B2 | Lipoic acid acylated salicylate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946451-B2 | Lipoic acid acylated salicylate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2011044138-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082192-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110082192-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082192-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | ACACA, ACAT2, ACACB | BCHE 3188/4885ACHE 3357/4885CA12 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.